Medicina
Departamento
Alfredo
Carrato Mena
Publicaciones en las que colabora con Alfredo Carrato Mena (71)
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: Reframe molecular study
Cancers, Vol. 13, Núm. 7
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain
Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26
-
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000
2020
-
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. 165-177
-
Treatment patterns for metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462
2019
-
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383
-
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
BMC Cancer, Vol. 19, Núm. 1
-
Management and supportive treatment of frail patients with metastatic pancreatic cancer
Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
-
Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts
Journal of Pain Research, Vol. 12, pp. 2349-2358
2018
-
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329
-
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial
Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444
-
Management of hyperbilirubinaemia in pancreatic cancer patients
European Journal of Cancer, Vol. 94, pp. 26-36
2017
-
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681
-
European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 288-290
-
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
European Journal of Cancer, Vol. 81, pp. 191-202